21,083 Shares in Catalyst Pharmaceuticals, Inc. $CPRX Purchased by Nomura Holdings Inc.

Key Points

• Nomura Holdings Inc. has acquired a new position in Catalyst Pharmaceuticals, purchasing 21,083 shares valued at approximately $511,000 during the first quarter.
• Insiders have been active, with Preethi Sundaram and Steve Miller selling shares, resulting in a total of 167,894 shares sold worth $3.43 million in the last quarter.
• Despite some analysts downgrading the stock's ratings, Catalyst Pharmaceuticals maintains a consensus rating of "Buy" and a target price of $33.20.

Nomura Holdings Inc. bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 21,083 shares of the biopharmaceutical company's stock, valued at approximately $511,000.

Several other hedge funds have also bought and sold shares of CPRX. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth $29,000. Sound Income Strategies LLC purchased a new position in Catalyst Pharmaceuticals in the first quarter worth $64,000. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Catalyst Pharmaceuticals by 57.2% during the first quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock valued at $133,000 after purchasing an additional 2,002 shares in the last quarter. Finally, US Bancorp DE raised its position in Catalyst Pharmaceuticals by 17.8% during the first quarter. US Bancorp DE now owns 7,328 shares of the biopharmaceutical company's stock valued at $178,000 after purchasing an additional 1,105 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Down 1.3%

Shares of NASDAQ:CPRX traded down $0.26 during midday trading on Wednesday, hitting $19.74. 1,653,130 shares of the stock traded hands, compared to its average volume of 1,451,078. The business's 50 day moving average is $20.77 and its two-hundred day moving average is $22.38. The stock has a market capitalization of $2.42 billion, a PE ratio of 11.96, a P/E/G ratio of 0.81 and a beta of 0.85. Catalyst Pharmaceuticals, Inc. has a one year low of $19.00 and a one year high of $26.58.

Insiders Place Their Bets

In related news, CEO Richard J. Daly sold 22,970 shares of the company's stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total transaction of $473,641.40. Following the completion of the transaction, the chief executive officer owned 226,794 shares in the company, valued at $4,676,492.28. This represents a 9.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David S. Tierney sold 26,000 shares of the firm's stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $20.20, for a total value of $525,200.00. Following the completion of the sale, the director directly owned 379,620 shares of the company's stock, valued at $7,668,324. The trade was a 6.41% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 243,970 shares of company stock worth $4,927,241. 10.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CPRX. Zacks Research cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, Wall Street Zen raised Catalyst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, September 5th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $33.20.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.